Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Σάββατο 4 Φεβρουαρίου 2017

Multimodal treatment of resectable pancreatic ductal adenocarcinoma

Publication date: Available online 4 February 2017
Source:Critical Reviews in Oncology/Hematology
Author(s): Nicola Silvestris, Oronzo Brunetti, Enrico Vasile, Francesco Cellini, Ivana Cataldo, Valeria Pusceddu, Monica Cattaneo, Stefano Partelli, Mario Scartozzi, Giuseppe Aprile, Andrea Casadei Gardini, Alessio Giuseppe Morganti, Vincenzo Valentini, Aldo Scarpa, Massimo Falconi, Angela Calabrese, Vito Lorusso, Michele Reni, Stefano Cascinu
After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients.



http://ift.tt/2kdxhZS

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου